Thought Leadership

A searchable library for all Cerner Enviza thought leadership across
multiple channels. For clinical publications please click here.

girl in car listening to music with pink headphones
How patients with rare cancers are getting ‘doubly hit’
Rare cancers (RC) are a heterogeneous group of conditions that can be associated with psychological and physical impairments. The incidence of RC is less than six cases per 100,000 people/year1 but altogether, RC diseases account for approximately 24% of all cancer cases diagnosed, higher than any single common cancer2–4. Despite advances in treatments and more long-term survivors living with cancer as a chronic illness5 , five-year relative survival rates are still lower for patients with RCs than common cancers (47% vs. 65%)3
China Inhibitor market graphic
Evolution of the immune checkpoint inhibitor market landscape in China
Recent regulatory developments and increasing domestic competition in China are now shaping development strategy for global companies
PearlsOfWisdom graphic
Pearls of wisdom: Rare Cancer
Investigate how incidence of rare cancers varies across the U.S, EU, Japan and China.
CART Infographic thumbnail
For the record: CAR-T therapy
An overview of CAR-T trials by clinical phase of development for hematological and solid tumors
ADC Hitting the right targets graphic
Hitting the right targets: An overview of current ADC trials
ADCs target tumor cells with toxic chemotherapy payloads. This interactive infographic detailing the extent of pivotal trial activity by developer, tumor type, molecular target, and payload chemotherapy class
head and neck cancer graphic
Head and neck cancer: Unique challenges require a holistic view
Unique challenges face H&N cancer patients, which gives rise to important considerations driving treatments decisions
SIgnposting a better path graphic
Signposting a path to better treatments
Trends in historical approvals and setbacks across different stages of disease in Esophageal, Pancreatic, Gastric, Hepatocellular, and Colorectal Cancers
Evolution of biomarker trials across the tumor spectrum
Biomarker driven clinical trials have quickly built momentum in oncology. Explore and understand two decades of developmental trends across a variety of tumors.
Pining hope on CDK4/6
While CDK4/6 inhibitors are at different stages of global adoption, they are indisputably the new standard of care bringing better outcomes to patients with HR+HER2- metastatic breast cancer.
The Breadth of PD(L)1 Development in 2021
Development of immuno-oncology drugs has risen dramatically. With 6 PD(L)1 agents now FDA approved, development now extends to multiple tumor types.
Navigating multiple myeloma
A more positive journey for patients with increased survival rates. View the some of the contributing factors over 2004 to 2014.
The expanding and evolving NSCLC immuno-therapy universe
Use of PD(L)1 monoclonal antibodies (mABs) in NSCLC clinical trials has surged from 3% in 2012 to over 50% in 2017-19. View infographic for more details.
The Oncology Race in Biotech
Many biotechs are looking for their first approval, including those with large clinical programs in the US and EU and ongoing Phase III trials.
Precision Medicine: The Next Generation
For too long oncology patients have been treated with a one-size-fits-all treatment plan. The time has come for a more personalized approach.
A Periodic Table of Biomarkers
Tumor-agnostic development strategies are gaining momentum as a way to treat solid and hematological tumors characterized by novel and existing biomarkers.
The burden of cancer caregiving across the globe
Data from the National Health & Wellness Survey suggests population aging and economic development influence the role of cancer caregivers and the degree of health, productivity, and financial impacts they report.
Better testing, better outcomes in Rare Cancer: BRCA mutation and PARP inhibitors
Could increased testing improve outcomes of more patients in rare cancer? And with HRR mutations occurring in multiple tumor types, are there more cancers these drugs can treat?
Better testing, better outcomes in Rare Cancer: NTRK fusions
The diverse nature of NTRK fusions present challenges for identification and diagnosis given their rarity and heterogenous patient populations.
CAR-T and the growth of cell therapy trials
While CAR-T therapies are the dominant approach globally with development focused in the US and China, other therapy approaches are steadily rising.